Los Angeles Capital Management LLC Eagle Pharmaceuticals, Inc. Transaction History

Los Angeles Capital Management LLC

$27.9 Billion
Q2 2024

A detailed history of Los Angeles Capital Management LLC transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Los Angeles Capital Management LLC holds 132,606 shares of EGRX stock, worth $538,380. This represents 0.0% of its overall portfolio holdings.

Number of Shares

132,606

Previous 191,732 30.84%

Holding current value

$538,380

Previous $1 Million 26.1%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	SELL	$3.34 - $5.6 $197,480 - $331,105	-59,126 Reduced 30.84%	132,606 $742,000
Q1 2024 Apr 05, 2024	BUY	$4.26 - $6.51 $428,002 - $654,059	100,470 Added 110.09%	191,732 $1 Million
Q4 2023 Feb 06, 2024	BUY	$4.63 - $15.21 $171,226 - $562,496	36,982 Added 68.13%	91,262 $477,000
Q3 2023 Nov 06, 2023	SELL	$15.21 - $22.88 $234,294 - $352,443	-15,404 Reduced 22.11%	54,280 $855,000
Q2 2023 Aug 03, 2023	SELL	$17.74 - $31.87 $87,475 - $157,150	-4,931 Reduced 6.61%	69,684 $1.35 Million
Q1 2023 May 04, 2023	BUY	$25.06 - $34.09 $810,415 - $1.1 Million	32,339 Added 76.49%	74,615 $2.12 Million
Q4 2022 Feb 06, 2023	BUY	$24.98 - $39.77 $1.06 Million - $1.68 Million	42,276 New	42,276 $1.24 Million
Q2 2022 Aug 05, 2022	SELL	$41.26 - $51.35 $372,825 - $463,998	-9,036 Reduced 20.82%	34,358 $1.53 Million
Q1 2022 May 06, 2022	BUY	$44.58 - $52.6 $199,540 - $235,437	4,476 Added 11.5%	43,394 $2.15 Million
Q4 2021 Feb 03, 2022	SELL	$45.82 - $56.9 $962 - $1,194	-21 Reduced 0.05%	38,918 $1.98 Million
Q3 2021 Nov 08, 2021	SELL	$43.79 - $55.78 $165,088 - $210,290	-3,770 Reduced 8.83%	38,939 $2.17 Million
Q2 2021 Aug 05, 2021	BUY	$36.86 - $44.5 $923,343 - $1.11 Million	25,050 Added 141.85%	42,709 $1.83 Million
Q1 2021 May 05, 2021	SELL	$40.32 - $50.97 $85,276 - $107,801	-2,115 Reduced 10.7%	17,659 $737,000
Q4 2020 Feb 04, 2021	SELL	$41.72 - $51.34 $766,605 - $943,372	-18,375 Reduced 48.17%	19,774 $921,000
Q3 2020 Nov 02, 2020	SELL	$37.02 - $51.28 $282,721 - $391,625	-7,637 Reduced 16.68%	38,149 $1.62 Million
Q2 2020 Aug 05, 2020	BUY	$43.24 - $55.02 $591,566 - $752,728	13,681 Added 42.61%	45,786 $2.2 Million
Q1 2020 May 04, 2020	BUY	$34.37 - $60.07 $374,976 - $655,363	10,910 Added 51.47%	32,105 $1.48 Million
Q3 2019 Nov 07, 2019	BUY	$53.25 - $59.98 $347,722 - $391,669	6,530 Added 44.53%	21,195 $1.2 Million
Q4 2018 Feb 11, 2019	BUY	$36.72 - $67.73 $77,662 - $143,248	2,115 Added 16.85%	14,665 $591,000
Q3 2018 Nov 05, 2018	BUY	$66.65 - $83.86 $836,457 - $1.05 Million	12,550 New	12,550 $870,000

Others Institutions Holding EGRX

# of Institutions

Shares Held

9.89M

Call Options Held

1.01M

Put Options Held

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $52.8M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.

Account

Los Angeles Capital Management LLC Eagle Pharmaceuticals, Inc. Transaction History